304 related articles for article (PubMed ID: 29883880)
1. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.
Reis R; Labat L; Allard M; Boudou-Rouquette P; Chapron J; Bellesoeur A; Thomas-Schoemann A; Arrondeau J; Giraud F; Alexandre J; Vidal M; Goldwasser F; Blanchet B
J Pharm Biomed Anal; 2018 Sep; 158():174-183. PubMed ID: 29883880
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous and rapid determination of 12 tyrosine kinase inhibitors by LC-MS/MS in human plasma: Application to therapeutic drug monitoring in patients with non-small cell lung cancer.
Zhou L; Wang S; Chen M; Huang S; Zhang M; Bao W; Bao A; Zhang P; Guo H; Liu Z; Xie G; Gao J; Wu Z; Lou Y; Fan G
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jun; 1175():122752. PubMed ID: 33991955
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry.
Xiong X; Zhang Y; Wang Z; Zhou C; Yang P; Du X; Yang L; Liu W
Clin Chim Acta; 2022 Feb; 527():1-10. PubMed ID: 34999058
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry.
Liu X; Li W; Zhang Y; Jiang Y; Zhao Q; Zhong D
J Pharm Biomed Anal; 2019 Nov; 176():112735. PubMed ID: 31394305
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer.
Hayashi H; Kita Y; Iihara H; Yanase K; Ohno Y; Hirose C; Yamada M; Todoroki K; Kitaichi K; Minatoguchi S; Itoh Y; Sugiyama T
Biomed Chromatogr; 2016 Jul; 30(7):1150-1154. PubMed ID: 26525154
[TBL] [Abstract][Full Text] [Related]
6. Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma.
Rood JJM; van Bussel MTJ; Schellens JHM; Beijnen JH; Sparidans RW
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Sep; 1031():80-85. PubMed ID: 27469903
[TBL] [Abstract][Full Text] [Related]
7. Quantification of afatinib, alectinib, crizotinib and osimertinib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry; focusing on the stability of osimertinib.
Veerman GDM; Lam MH; Mathijssen RHJ; Koolen SLW; de Bruijn P
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Apr; 1113():37-44. PubMed ID: 30889498
[TBL] [Abstract][Full Text] [Related]
8. An Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Afatinib, Alectinib, Ceritinib, Crizotinib, Dacomitinib, Erlotinib, Gefitinib, and Osimertinib in Human Serum.
Mukai Y; Wakamoto A; Hatsuyama T; Yoshida T; Sato H; Fujita A; Inotsume N; Toda T
Ther Drug Monit; 2021 Dec; 43(6):772-779. PubMed ID: 33871406
[TBL] [Abstract][Full Text] [Related]
9. Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS.
Li Y; Meng L; Ma Y; Li Y; Xing X; Guo C; Dong Z
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889345
[TBL] [Abstract][Full Text] [Related]
10. Bioanalysis of EGFRm inhibitor osimertinib, and its glutathione cycle- and desmethyl metabolites by liquid chromatography-tandem mass spectrometry.
Rood JJM; van Haren MJ; Beijnen JH; Sparidans RW
J Pharm Biomed Anal; 2020 Jan; 177():112871. PubMed ID: 31539712
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of an HPLC-MS/MS method to simultaneously quantify alectinib, crizotinib, erlotinib, gefitinib and osimertinib in human plasma samples, using one assay run.
van Veelen A; van Geel R; Schoufs R; de Beer Y; Stolk LM; Hendriks LEL; Croes S
Biomed Chromatogr; 2021 Dec; 35(12):e5224. PubMed ID: 34363425
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma.
Aghai F; Zimmermann S; Kurlbaum M; Jung P; Pelzer T; Klinker H; Isberner N; Scherf-Clavel O
Anal Bioanal Chem; 2021 Jan; 413(2):599-612. PubMed ID: 33155133
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serum.
Ishikawa E; Yokoyama Y; Chishima H; Kuniyoshi O; Sato I; Nakaya N; Nakajima H; Kimura M; Hakamata J; Suehiro N; Nakada H; Ikemura S; Jibiki A; Kawazoe H; Muramatsu H; Suzuki S; Nakamura T
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 May; 1199():123245. PubMed ID: 35436724
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
[TBL] [Abstract][Full Text] [Related]
15. Determining plasma and cerebrospinal fluid concentrations of EGFR-TKI in lung cancer patients.
Chen GY; Liang SK; Wei YF; Weng TI; Chen KY
Anal Biochem; 2023 May; 669():115115. PubMed ID: 36931580
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.
Tartarone A; Lazzari C; Lerose R; Conteduca V; Improta G; Zupa A; Bulotta A; Aieta M; Gregorc V
Lung Cancer; 2013 Sep; 81(3):328-336. PubMed ID: 23809060
[TBL] [Abstract][Full Text] [Related]
17. Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
Tamiya M; Tamiya A; Suzuki H; Moriizumi K; Nakahama K; Taniguchi Y; Kunimasa K; Kimura M; Inoue T; Kuhara H; Nishino K; Hirashima T; Atagi S; Imamura F; Kumagai T
Anticancer Res; 2019 Jul; 39(7):3923-3929. PubMed ID: 31262922
[TBL] [Abstract][Full Text] [Related]
18. Determination of tyrosine kinase inhibitor afatinib in rat plasma using LC-MS/MS and its application to in vivo pharmacokinetic studies of afatinib liposomes.
Lu X; Liu S; Yang X; Han M; Sun K
J Pharm Biomed Anal; 2019 Feb; 164():181-186. PubMed ID: 30390560
[TBL] [Abstract][Full Text] [Related]
19. A Validated Assay to Quantify Osimertinib and Its Metabolites, AZ5104 and AZ7550, from Microsampled Dried Blood Spots and Plasma.
Venkatesh B; Yuile A; McKay MJ; Narayanan S; Wheeler H; Itchins M; Pavlakis N; Clarke SJ; Molloy MP
Ther Drug Monit; 2024 Jun; 46(3):332-343. PubMed ID: 38263583
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous Quantitation of Anlotinib and Osimertinib by Isotope-Labeled UHPLC-MS/MS in Human Plasma: Application in NSCLC Patients.
Liu Y; Lin Z; Luo W; Pei X; She Z; Sha Z; Guan Y; Ming D; Liang J
J Chromatogr Sci; 2024 Apr; 62(4):339-346. PubMed ID: 37070405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
